Carregant...
Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy
PURPOSE: We determined the response rate to and safety of a dual 5α-reductase inhibitor, dutasteride, in men with castration recurrent prostate cancer. MATERIALS AND METHODS: A total of 28 men with asymptomatic castration recurrent prostate cancer were treated with 3.5 mg dutasteride daily (luteiniz...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2851185/ https://ncbi.nlm.nih.gov/pubmed/19091347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2008.10.014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|